Bone Density, Breast Cancer
Conditions
Keywords
Arimidex, Bone Mineral density, Bisphosphonates, Aromatase Inhibitors
Brief summary
To investigate the management of bone health in postmenopausal women with early breast cancer (BCA) scheduled to receive anastrozole. Postmenopausal women with hormone receptor-positive early BCA are assigned to 1 of 3 strata depending on their pre-existing risk of fragility fracture. Patients (pts) with a bone mineral density (BMD) T-score \<-2.0 for either spine or hip are designated higher-risk (H) for fracture and receive anastrozole 1 mg/day plus risedronate orally. Moderate-risk (M) pts (T-score \<-1.0 for spine or hip but -2.0 at both sites) are randomized to receive anastrozole plus risedronate (A+R) or anastrozole alone. Pts with T-scores -1.0 at both spine and hip were designated lower-risk (L) and receive anastrozole alone. All pts receive calcium and vitamin D. Lumbar spine and total hip BMD are assessed at baseline, 12, and 24 months.
Interventions
None listed
Sponsors
Hellenic Breast Surgeons Society
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Postmenopausal women * ER and or PgR positive breast cancer * Completed Surgery and =/- chemotherapy
Exclusion criteria
* metastases * history of fractures * HRT or SERMs * Liver or kidney disfunction
Countries
Greece
Outcome results
None listed